FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313143392> ?p ?o ?g. }

• W2313143392 endingPage "19" @default.
• W2313143392 startingPage "6" @default.
• W2313143392 abstract "Background Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism is a frequent complication in immobile patients with acute ischemic stroke. This guideline document presents the European Stroke Organisation guidelines for the prophylaxis of VTE in immobile patients with acute ischaemic stroke. Guidelines for haemorrhagic stroke have already been published. Methods A multidisciplinary group identified related questions and developed its recommendations based on evidence from randomised controlled trials using the Grading of Recommendations Assessment, Development, and Evaluation approach. This guideline document was reviewed within the European Stroke Organisation and externally and was approved by the European Stroke Organisation Guidelines Committee and the European Stroke Organisation Executive Committee. Results We found mainly moderate quality evidence comprising randomised controlled trials and systematic reviews evaluating graduated compression stockings (GCS), intermittent pneumatic compression (IPC) and prophylactic anticoagulation with unfractionated (UFH) and low molecular weight heparins (LMWH) and heparinoids, but no randomised trials evaluating neuromuscular electrical stimulation (NES). We recommend that clinicians should use IPC in immobile patients, but that they should not use GCS. Prophylactic anticoagulation with UFH (5000U ×2, or ×3 daily) or LMWH or heparinoid should be considered in immobile patients with ischaemic stroke in whom the benefits of reducing the risk of VTE is high enough to offset the increased risks of intracranial and extracranial bleeding associated with their use. Where a judgement has been made that prophylactic anticoagulation is indicated LMWH or heparinoid should be considered instead of UFH because of its greater reduction in risk of DVT, the greater convenience, reduced staff costs and patient comfort associated single vs. multiple daily injections but these advantages should be weighed against the higher risk of extracranial bleeding, higher drug costs and risks in elderly patients with poor renal function associated with LMWH and heparinoids. Conclusions IPC, UFH or LMWH and heparinoids can reduce the risk of VTE in immobile patients with acute ischaemic stroke but further research is required to test whether NES is effective. The strongest evidence is for IPC. Better methods are needed to help stratify patients in the first few weeks after stroke onset, by their risk of VTE and their risk of bleeding on anticoagulants." @default.
• W2313143392 created "2016-06-24" @default.
• W2313143392 creator A5022665738 @default.
• W2313143392 creator A5029838434 @default.
• W2313143392 creator A5034038759 @default.
• W2313143392 creator A5050413666 @default.
• W2313143392 creator A5053432718 @default.
• W2313143392 date "2016-03-01" @default.
• W2313143392 modified "2023-10-16" @default.
• W2313143392 title "European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke" @default.
• W2313143392 cites W1498265361 @default.
• W2313143392 cites W155086105 @default.
• W2313143392 cites W1571077906 @default.
• W2313143392 cites W1789801172 @default.
• W2313143392 cites W1998452547 @default.
• W2313143392 cites W2013144056 @default.
• W2313143392 cites W2031822163 @default.
• W2313143392 cites W2034909575 @default.
• W2313143392 cites W2034995926 @default.
• W2313143392 cites W2045469463 @default.
• W2313143392 cites W2052502009 @default.
• W2313143392 cites W2053280564 @default.
• W2313143392 cites W2069994182 @default.
• W2313143392 cites W2071133363 @default.
• W2313143392 cites W2078482247 @default.
• W2313143392 cites W2093770528 @default.
• W2313143392 cites W2096535216 @default.
• W2313143392 cites W2112457251 @default.
• W2313143392 cites W2120103059 @default.
• W2313143392 cites W2120721286 @default.
• W2313143392 cites W2121822256 @default.
• W2313143392 cites W2123108652 @default.
• W2313143392 cites W2129304653 @default.
• W2313143392 cites W2134236426 @default.
• W2313143392 cites W2135533213 @default.
• W2313143392 cites W2136946774 @default.
• W2313143392 cites W2148305501 @default.
• W2313143392 cites W2150124983 @default.
• W2313143392 cites W2152538959 @default.
• W2313143392 cites W2165010366 @default.
• W2313143392 cites W2165168223 @default.
• W2313143392 cites W2166201242 @default.
• W2313143392 cites W2167182432 @default.
• W2313143392 cites W2289101122 @default.
• W2313143392 cites W2313868127 @default.
• W2313143392 cites W2409211243 @default.
• W2313143392 cites W2574621464 @default.
• W2313143392 cites W2762985035 @default.
• W2313143392 cites W3014186398 @default.
• W2313143392 cites W4247469365 @default.
• W2313143392 cites W4290749263 @default.
• W2313143392 doi "https://doi.org/10.1177/2396987316628384" @default.
• W2313143392 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6301216" @default.
• W2313143392 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31008263" @default.
• W2313143392 hasPublicationYear "2016" @default.
• W2313143392 type Work @default.
• W2313143392 sameAs 2313143392 @default.
• W2313143392 citedByCount "34" @default.
• W2313143392 countsByYear W23131433922016 @default.
• W2313143392 countsByYear W23131433922018 @default.
• W2313143392 countsByYear W23131433922019 @default.
• W2313143392 countsByYear W23131433922020 @default.
• W2313143392 countsByYear W23131433922021 @default.
• W2313143392 countsByYear W23131433922022 @default.
• W2313143392 countsByYear W23131433922023 @default.
• W2313143392 crossrefType "journal-article" @default.
• W2313143392 hasAuthorship W2313143392A5022665738 @default.
• W2313143392 hasAuthorship W2313143392A5029838434 @default.
• W2313143392 hasAuthorship W2313143392A5034038759 @default.
• W2313143392 hasAuthorship W2313143392A5050413666 @default.
• W2313143392 hasAuthorship W2313143392A5053432718 @default.
• W2313143392 hasBestOaLocation W23131433921 @default.
• W2313143392 hasConcept C126322002 @default.
• W2313143392 hasConcept C127413603 @default.
• W2313143392 hasConcept C141071460 @default.
• W2313143392 hasConcept C142724271 @default.
• W2313143392 hasConcept C177713679 @default.
• W2313143392 hasConcept C1862650 @default.
• W2313143392 hasConcept C2776265017 @default.
• W2313143392 hasConcept C2776301958 @default.
• W2313143392 hasConcept C2776884760 @default.
• W2313143392 hasConcept C2778890739 @default.
• W2313143392 hasConcept C2778959117 @default.
• W2313143392 hasConcept C2779161974 @default.
• W2313143392 hasConcept C2780182762 @default.
• W2313143392 hasConcept C2780645631 @default.
• W2313143392 hasConcept C2780868729 @default.
• W2313143392 hasConcept C71924100 @default.
• W2313143392 hasConcept C78519656 @default.
• W2313143392 hasConceptScore W2313143392C126322002 @default.
• W2313143392 hasConceptScore W2313143392C127413603 @default.
• W2313143392 hasConceptScore W2313143392C141071460 @default.
• W2313143392 hasConceptScore W2313143392C142724271 @default.
• W2313143392 hasConceptScore W2313143392C177713679 @default.
• W2313143392 hasConceptScore W2313143392C1862650 @default.
• W2313143392 hasConceptScore W2313143392C2776265017 @default.
• W2313143392 hasConceptScore W2313143392C2776301958 @default.
• W2313143392 hasConceptScore W2313143392C2776884760 @default.

• next